Clinical Trials Logo

Crohn's Disease clinical trials

View clinical trials related to Crohn's Disease.

Filter by:

NCT ID: NCT02942511 Completed - Crohn's Disease Clinical Trials

Predictors Favoring the Role of Exclusive Enteral Nutrition in Active Crohn's Disease

Start date: January 1, 2014
Phase:
Study type: Observational

To idetify the factors favoring the use of enteral nutrition would be helpful to select preferred patients suitable for enteral nutrition.

NCT ID: NCT02940054 Recruiting - Crohn's Disease Clinical Trials

RED-FLAGS Index Validation in Crohn's Disease Patients

RED-FLAGS2
Start date: February 2015
Phase: N/A
Study type: Observational

Observational prospective study to validate a new index for early diagnosis of Crohn's disease (CD)

NCT ID: NCT02930564 Terminated - Crohn's Disease Clinical Trials

The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission

Start date: January 2017
Phase: N/A
Study type: Interventional

The Challenge study is a prospective, open label, pilot trial in patients in deep remission on dietary maintenance therapy. The purpose of this study is to determine whether they can consume some of the products that were eliminated from their diet, named the Crohn's Disease Exclusion Diet (CDED), and to evaluate if low dose exposure is harmful.

NCT ID: NCT02926300 Recruiting - Crohn's Disease Clinical Trials

Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

Start date: November 2015
Phase: N/A
Study type: Observational

The purpose of this clinical trial is to evaluate long-term safety and efficacy in patients who has history of FURESTEM-CD injection at least once.

NCT ID: NCT02914600 Terminated - Crohn's Disease Clinical Trials

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

DIVERSITYLTE
Start date: March 17, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).

NCT ID: NCT02914561 Completed - Crohn's Disease Clinical Trials

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

DIVERSITY1
Start date: October 31, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Study GS-US-419-3896).

NCT ID: NCT02913508 Withdrawn - Ulcerative Colitis Clinical Trials

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the bioavailability and pharmacokinetics (PK) of multiple doses of vedolizumab subcutaneous (SC) compared to vedolizumab intravenous (IV).

NCT ID: NCT02896985 Completed - Crohn's Disease Clinical Trials

Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )

PRADA
Start date: December 16, 2016
Phase:
Study type: Observational

This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).

NCT ID: NCT02891226 Completed - Crohn's Disease Clinical Trials

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

SERENITY
Start date: December 14, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.

NCT ID: NCT02883452 Completed - Crohn's Disease Clinical Trials

A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis

Start date: September 29, 2016
Phase: Phase 1
Study type: Interventional

Phase 1 randomized, open-label, multicenter, parallel-group study designed to evaluate efficacy, pharmacokinetics and safety between CT-P13 subcutaneous (SC) and CT-P13 intravenous (IV) in patients with active Crohn's Disease (CD) and active Ulcerative Colitis (UC).